PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRipretinib
Qinlock(ripretinib)
Qinlock (ripretinib) is a small molecule pharmaceutical. Ripretinib was first approved as Qinlock on 2020-05-15. It is used to treat gastrointestinal stromal tumors in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors. It is known to target mast/stem cell growth factor receptor Kit.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Qinlock
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ripretinib
Tradename
Company
Number
Date
Products
QINLOCKDeciphera PharmaceuticalsN-213973 RX2020-05-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
qinlockNew Drug Application2024-11-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gastrointestinal stromal tumorsEFO_0000505D046152C49.A
Agency Specific
FDA
EMA
Expiration
Code
RIPRETINIB, QINLOCK, DECIPHERA PHARMS
2027-05-15ODE-298
2025-05-15NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Ripretinib, Qinlock, Deciphera Pharms
117795722042-10-06U-3714
111855352040-12-30DP
113958182040-12-30DP
115769032040-12-30DP
116125912040-12-30DP
117937952040-12-30DP
118012372040-12-30DPU-3219
118447882040-12-30DP
118502402040-12-30DP
118502412040-12-30DP
118965852040-12-30DP
119039332040-12-30DP
109669662040-08-12U-3153
112666352040-08-12U-3330
113445362040-08-12U-3381
114263902040-08-12U-3416
114330562040-08-12U-3423
115293362040-08-12U-3382
115344322040-08-12U-3442
115769042040-08-12U-3537
118132512040-08-12U-3750
84611792034-05-15DS, DP
RE487312032-06-07U-3219
81881132030-07-27DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX19: Ripretinib
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A653—718
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8042———4
Gastrointestinal diseasesD005767——21———2
Digestive system diseasesD004066HP_0011024K92.921———2
Gastrointestinal neoplasmsD005770—C26.911———1
Digestive system neoplasmsD004067——11———1
Neoplasms by histologic typeD009370——11———1
Connective and soft tissue neoplasmsD018204——11———1
Connective tissue neoplasmsD009372——11———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic mastocytosisD034721—C96.211————1
MastocytosisD008415—D47.091————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRipretinib
INNripretinib
Description
Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.
Classification
Small molecule
Drug classretinol derivatives; tyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Identifiers
PDB—
CAS-ID1225278-16-9
RxCUI—
ChEMBL IDCHEMBL4216467
ChEBI ID—
PubChem CID71584930
DrugBankDB14840
UNII ID9XW757O13D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KIT
KIT
Organism
Homo sapiens
Gene name
KIT
Gene synonyms
SCFR
NCBI Gene ID
3815
Protein name
mast/stem cell growth factor receptor Kit
Protein synonyms
c-Kit protooncogene, CD117, p145 c-kit, PBT, Piebald trait protein, Proto-oncogene c-Kit, proto-oncogene tyrosine-protein kinase Kit, Tyrosine-protein kinase Kit, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein
Uniprot ID
Q9UM99
Mouse ortholog
Kit (16590)
mast/stem cell growth factor receptor Kit (Q8C8K9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Qinlock – Zai Lab
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 454 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,054 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use